Drilon A, et al. - This study encompassed an analysis of the efficacy and safety of larotrectinib, a highly selective tropomyosin receptor kinases (TRK) inhibitor, in adults and children who had tumors with fusions involving one of 3 TRKs. It was reported that no patients discontinued larotrectinib due to drug-related adverse events. Findings illustrated that larotrectinib displayed significant and durable antitumor activity in patients with TRK fusion–positive cancer, irrespective of the age of the patient or of the tumor type.